OncoMatch/Clinical Trials/NCT07255963
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Is NCT07255963 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pirtobrutinib and Lisaftoclax for dlbcl - diffuse large b cell lymphoma.
Treatment: Pirtobrutinib · Lisaftoclax · Rituximab — This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic therapy — DLBCL
Have received at least one prior line of systemic therapy for DLBCL.
Cannot have received: pirtobrutinib (pirtobrutinib)
Prior treatment failure or resistance to pirtobrutinib
Cannot have received: BCL2 inhibitor
Prior treatment failure or resistance to BCL2 inhibitors
Cannot have received: chemotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: radiotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: immunotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: antibody-based anticancer therapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: traditional Chinese herbal medicine with antitumor indications
Traditional Chinese herbal medicine with antitumor indications.
Cannot have received: small-molecule targeted therapy
Exception: within 2 weeks before study treatment initiation
Small-molecule targeted therapy within 2 weeks before study treatment initiation.
Cannot have received: antibody-drug conjugate
Exception: within 10 weeks before study treatment initiation
ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
Cannot have received: cytotoxic chemotherapy
Exception: within 10 weeks before study treatment initiation
ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation (HSCT) or planned allogeneic HSCT.
Lab requirements
Blood counts
anc≥1.5 × 10⁹/l, platelets ≥80 × 10⁹/l, hemoglobin ≥80 g/l
Kidney function
serum creatinine ≤1.5 × uln or estimated creatinine clearance (crcl) ≥60 ml/min
Liver function
total bilirubin ≤1.5 × uln (≤3.0 × uln if liver metastases present); ast/sgot and alt/sgpt ≤2.5 × uln (≤5.0 × uln if liver metastases present)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07255963 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pirtobrutinib, BCL2 inhibitor, chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify